{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:13:04Z","timestamp":1793412784270,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2023MH144"],"award-info":[{"award-number":["ZR2023MH144"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019446","name":"Medical and Health Science and Technology Development Project of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.peptides.2025.171429","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:33:54Z","timestamp":1752712434000},"page":"171429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Liraglutide suppresses ferroptosis by upregulation NRF2 in type 2 diabetic cardiomyopathy"],"prefix":"10.1016","volume":"192","author":[{"given":"Xuepin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo an","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2025.171429_bib1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41420-023-01553-4","article-title":"Diabetic cardiomyopathy: early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions","volume":"9","author":"Huo","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.peptides.2025.171429_bib2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10741-021-10200-y","article-title":"Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants","volume":"28","author":"Prandi","year":"2023","journal-title":"Heart Fail Rev."},{"key":"10.1016\/j.peptides.2025.171429_bib3","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/ejhf.3347","article-title":"Diabetic myocardial disorder. a clinical consensus statement of the heart failure association of the ESC and the ESC working group on myocardial & pericardial diseases","volume":"26","author":"Seferovi\u0107","year":"2024","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.peptides.2025.171429_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.707336","article-title":"Novel insights into the pathogenesis of diabetic cardiomyopathy and pharmacological strategies","volume":"8","author":"Mu\u00f1oz-C\u00f3rdova","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.peptides.2025.171429_bib5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.apsb.2021.10.005","article-title":"Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK\/NRF2 pathways","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.peptides.2025.171429_bib6","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1073\/pnas.1821022116","article-title":"Ferroptosis as a target for protection against cardiomyopathy","volume":"116","author":"Fang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.peptides.2025.171429_bib7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/j.2040-4603.2020.tb00123.x","article-title":"Glucagon-Like Peptide-1: actions and influence on pancreatic hormone function","volume":"10","author":"Davis","year":"2020","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.peptides.2025.171429_bib8","doi-asserted-by":"crossref","first-page":"16489","DOI":"10.1096\/fj.202000860RR","article-title":"Incretin drugs effect on epigenetic machinery: new potential therapeutic implications in preventing vascular diabetic complications","volume":"34","author":"Scisciola","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.peptides.2025.171429_bib9","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41598-022-05323-7","article-title":"Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis","volume":"12","author":"Meurot","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.peptides.2025.171429_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.peptides.2025.171429_bib11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.peptides.2025.171429_bib12","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.peptides.2025.171429_bib13","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2025.171429_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2025.171429_bib15","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.peptides.2025.171429_bib16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.peptides.2025.171429_bib17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s12020-016-1166-4","article-title":"Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure","volume":"57","author":"Arturi","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.peptides.2025.171429_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2025.171429_bib19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.atherosclerosis.2015.03.026","article-title":"GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats","volume":"240","author":"Inoue","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.peptides.2025.171429_bib20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bbrc.2022.09.018","article-title":"Independent and combined effects of liraglutide and aerobic interval training on glycemic control and cardiac protection in diabetic cardiomyopathy rats","volume":"629","author":"Cai","year":"2022","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.peptides.2025.171429_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s10020-023-00721-7","article-title":"Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK\/ACC signaling and inhibiting ferroptosis","volume":"29","author":"Guo","year":"2023","journal-title":"Mol. Med"},{"key":"10.1016\/j.peptides.2025.171429_bib22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11064-021-03442-7","article-title":"Liraglutide alleviates cognitive deficit in db\/db mice: involvement in oxidative stress, iron overload, and ferroptosis","volume":"47","author":"An","year":"2022","journal-title":"Neurochem. Res"},{"key":"10.1016\/j.peptides.2025.171429_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101107","article-title":"NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis","volume":"23","author":"Dodson","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.peptides.2025.171429_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.28251","article-title":"Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells","volume":"63","author":"Sun","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.peptides.2025.171429_bib25","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1111\/jcmm.17275","article-title":"Therapeutic potentials of cell death inhibitors in rats with cardiac ischaemia\/reperfusion injury","volume":"27","author":"Luo","year":"2022","journal-title":"J. Cell Mol. Med"},{"key":"10.1016\/j.peptides.2025.171429_bib26","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2337\/dc21-1113","article-title":"Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes","volume":"45","author":"Wright","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2025.171429_bib27","first-page":"140","article-title":"The GLP-1R agonist liraglutide increases myocardial glucose oxidation rates via indirect mechanisms and mitigates experimental diabetic cardiomyopathy","volume":"37","author":"Almutairi","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.peptides.2025.171429_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2019.108241","article-title":"The effects of iron overload on mitochondrial function, mitochondrial dynamics, and ferroptosis in cardiomyocytes","volume":"680","author":"Sumneang","year":"2020","journal-title":"Arch. Biochem Biophys."},{"key":"10.1016\/j.peptides.2025.171429_bib29","doi-asserted-by":"crossref","first-page":"1140644","DOI":"10.3389\/fendo.2023.1140644","article-title":"Ferroptosis: roles and molecular mechanisms in diabetic cardiomyopathy","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.peptides.2025.171429_bib30","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3094504","article-title":"Liraglutide activates the Nrf2\/GPX4 antioxidant pathway and protects brain nerve cells against cerebral ischemia in diabetic rats","author":"Deng","year":"2018","journal-title":"Comput. Intell. Neurosci."}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978125000907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978125000907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:21:51Z","timestamp":1772749311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978125000907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":30,"alternative-id":["S0196978125000907"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2025.171429","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liraglutide suppresses ferroptosis by upregulation NRF2 in type 2 diabetic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2025.171429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"171429"}}